Skip to content

Residual Exacerbations With Mepolizumab

Asthma

This will be a two-year prospective study to characterize the nature of the remaining asthma exacerbations in patients treated with mepolizumab. Participants will be assessed every six months from pre- until two years of treatment in addition to whenever they experience an exacerbation of asthma during the study period. During these visits, various clinical, physiological and inflammatory outcomes will be assessed.

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    18 to 90

Participation Criteria

Inclusion Criteria:

* With a proven diagnosis of severe asthma as defined by the Canadian Thoracic Society
* Eligible for mepolizumab treatment
* Able and willing to sign the informed consent form

Exclusion Criteria:

* Any respiratory disease apart from asthma
* Confounding comorbidities sur as eosinophilic granulomatosis with polyangiitis (EGPA) or hypereosinophilic syndrome

Study Location

Institut universitaire de cardiologie et de pneumologie de Québec
Institut universitaire de cardiologie et de pneumologie de Québec
Québec, Quebec
Canada

Contact Study Team

Backup Contact

Marie-Eve Boulay

[email protected]
4186568711
Primary Contact

Andréanne Côté, MD-MSc

[email protected]
4186564747
Study Sponsored By
Laval University
Participants Required
More Information
Study ID: NCT04578171